Cover Image
市場調查報告書

肥胖症:開發中產品分析

Obesity - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232860
出版日期 內容資訊 英文 537 Pages
訂單完成後即時交付
價格
Back to Top
肥胖症:開發中產品分析 Obesity - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 537 Pages
簡介

肥胖症可說是身體屯積過多脂肪的狀態,會提升心臟病、糖尿病、高血壓等疾病之風險。其原因有年齡、家族遺傳、禁煙、睡眠不足、部分藥品等,治療方法有健康生活、服藥、手術等。

本報告涵括全球肥胖症治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

肥胖症概要

治療藥的開發

肥胖症:企業開發中的治療藥

肥胖症:大學/機關研究中的治療藥

肥胖症:開發中產品概況

肥胖症:企業開發中的產品

肥胖症:大學/機關研究中的產品

肥胖症的治療藥的開發企業

肥胖症:治療藥的評估

藥物簡介

肥胖症:最近的開發平台趨勢

肥胖症:暫停中的計劃

肥胖症:開發中止的產品

肥胖症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8621IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2016, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 16, 128, 33 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 46 and 14 molecules, respectively.Obesity.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Obesity Overview
  • Therapeutics Development
  • Obesity - Therapeutics under Development by Companies
  • Obesity - Therapeutics under Investigation by Universities/Institutes
  • Obesity - Pipeline Products Glance
  • Obesity - Products under Development by Companies
  • Obesity - Products under Investigation by Universities/Institutes
  • Obesity - Companies Involved in Therapeutics Development
  • Obesity - Therapeutics Assessment
  • Drug Profiles
  • Obesity - Dormant Projects
  • Obesity - Discontinued Products
  • Obesity - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Obesity, H2 2016
  • Number of Products under Development for Obesity - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Obesity - Pipeline by Abeome Corporation, H2 2016
  • Obesity - Pipeline by Acylin Therapeutics Inc, H2 2016
  • Obesity - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2016
  • Obesity - Pipeline by Akron Molecules AG, H2 2016
  • Obesity - Pipeline by Alize Pharma SAS, H2 2016
  • Obesity - Pipeline by Amabiotics SAS, H2 2016
  • Obesity - Pipeline by Amgen Inc., H2 2016
  • Obesity - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016
  • Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Obesity - Pipeline by AstraZeneca Plc, H2 2016
  • Obesity - Pipeline by Asubio Pharma Co., Ltd., H2 2016
  • Obesity - Pipeline by Athersys, Inc., H2 2016
  • Obesity - Pipeline by Biophytis SAS, H2 2016
  • Obesity - Pipeline by BioRestorative Therapies, Inc., H2 2016
  • Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Obesity - Pipeline by Braasch Biotech LLC, H2 2016
  • Obesity - Pipeline by C3 Jian, Inc, H2 2016
  • Obesity - Pipeline by Carmot Therapeutics Inc, H2 2016
  • Obesity - Pipeline by Chronos Therapeutics Limited, H2 2016
  • Obesity - Pipeline by CohBar, Inc., H2 2016
  • Obesity - Pipeline by CoMentis, Inc., H2 2016
  • Obesity - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
  • Obesity - Pipeline by Corium International, Inc., H2 2016
  • Obesity - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Obesity - Pipeline by Diabetica Limited, H2 2016
  • Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2016
  • Obesity - Pipeline by Eli Lilly and Company, H2 2016
  • Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2016
  • Obesity - Pipeline by Eternygen GmbH, H2 2016
  • Obesity - Pipeline by Evotec AG, H2 2016
  • Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Obesity - Pipeline by FibroGen Inc, H2 2016
  • Obesity - Pipeline by Galenea Corp., H2 2016
  • Obesity - Pipeline by Gila Therapeutics Inc, H2 2016
  • Obesity - Pipeline by Gilead Sciences, Inc., H2 2016
  • Obesity - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Obesity - Pipeline by GTx, Inc., H2 2016
  • Obesity - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Obesity - Pipeline by Handok Inc., H2 2016
  • Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Obesity - Pipeline by Immungenetics AG, H2 2016
  • Obesity - Pipeline by Intarcia Therapeutics, Inc., H2 2016
  • Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Obesity - Pipeline by Ixchel Pharma, LLC, H2 2016
  • Obesity - Pipeline by Jenrin Discovery, Inc., H2 2016
  • ity - Pipeline by Johnson & Johnson, H2 2016
  • Obesity - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Obesity - Pipeline by Leading BioSciences, Inc., H2 2016
  • Obesity - Pipeline by LEO Pharma A/S, H2 2016
  • Obesity - Pipeline by LG Life Science LTD., H2 2016
  • Obesity - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
  • Obesity - Pipeline by M Pharmaceutical Inc., H2 2016
  • Obesity - Pipeline by Magnus Life Ltd, H2 2016
  • Obesity - Pipeline by MAKScientific, LLC, H2 2016
  • Obesity - Pipeline by MedImmune LLC, H2 2016
  • Obesity - Pipeline by Merck & Co., Inc., H2 2016
  • Obesity - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Obesity - Pipeline by NeuroNano Pharma Inc, H2 2016
  • Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
  • Obesity - Pipeline by NIBEC, H2 2016
  • Obesity - Pipeline by Nordic Bioscience A/S, H2 2016
  • Obesity - Pipeline by Novo Nordisk A/S, H2 2016
  • Obesity - Pipeline by ObeTherapy Biotechnology, H2 2016
  • Obesity - Pipeline by Ogeda SA, H2 2016
  • Obesity - Pipeline by Omeros Corporation, H2 2016
  • Obesity - Pipeline by OPKO Biologics Ltd, H2 2016
  • Obesity - Pipeline by OPKO Health, Inc., H2 2016
  • Obesity - Pipeline by Orbis Biosciences Inc, H2 2016
  • Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2016
  • Obesity - Pipeline by Pfizer Inc., H2 2016
  • Obesity - Pipeline by PharmaIN Corporation, H2 2016
  • Obesity - Pipeline by Poxel SA, H2 2016
  • Obesity - Pipeline by Progenra, Inc., H2 2016
  • Obesity - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Obesity - Pipeline by ReCyte Therapeutics, Inc., H2 2016
  • Obesity - Pipeline by Renova Therapeutics Inc, H2 2016
  • Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Obesity - Pipeline by Saniona AB, H2 2016
  • Obesity - Pipeline by Sanofi, H2 2016
  • Obesity - Pipeline by Selvita S.A., H2 2016
  • Obesity - Pipeline by Seoul Pharma Co., Ltd., H2 2016
  • Obesity - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016
  • Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Obesity - Pipeline by Toray Industries, Inc., H2 2016
  • Obesity - Pipeline by Umecrine AB, H2 2016
  • Obesity - Pipeline by Vicore Pharma AB, H2 2016
  • Obesity - Pipeline by Viking Therapeutics, Inc., H2 2016
  • Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
  • Obesity - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
  • Obesity - Pipeline by XL-protein GmbH, H2 2016
  • Obesity - Pipeline by Yuyu Pharma, Inc., H2 2016
  • 1`Obesity - Pipeline by Zafgen Inc., H2 2016
  • Obesity - Pipeline by Zealand Pharma A/S, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Obesity - Dormant Projects, H2 2016
  • Obesity - Dormant Projects (Contd..1), H2 2016
  • Obesity - Dormant Projects (Contd..2), H2 2016
  • Obesity - Dormant Projects (Contd..3), H2 2016
  • Obesity - Dormant Projects (Contd..4), H2 2016
  • Obesity - Dormant Projects (Contd..5), H2 2016
  • Obesity - Dormant Projects (Contd..6), H2 2016
  • Obesity - Dormant Projects (Contd..7), H2 2016
  • Obesity - Dormant Projects (Contd..8), H2 2016
  • Obesity - Dormant Projects (Contd..9), H2 2016
  • Obesity - Dormant Projects (Contd..10), H2 2016
  • Obesity - Dormant Projects (Contd..11), H2 2016
  • Obesity - Dormant Projects (Contd..12), H2 2016
  • Obesity - Dormant Projects (Contd..13), H2 2016
  • Obesity - Dormant Projects (Contd..14), H2 2016
  • Obesity - Dormant Projects (Contd..15), H2 2016
  • Obesity - Dormant Projects (Contd..16), H2 2016
  • Obesity - Dormant Projects (Contd..17), H2 2016
  • Obesity - Dormant Projects (Contd..18), H2 2016
  • Obesity - Dormant Projects (Contd..19), H2 2016
  • Obesity - Dormant Projects (Contd..20), H2 2016
  • Obesity - Dormant Projects (Contd..21), H2 2016
  • Obesity - Dormant Projects (Contd..22), H2 2016
  • Obesity - Dormant Projects (Contd..23), H2 2016
  • Obesity - Dormant Projects (Contd..24), H2 2016
  • Obesity - Discontinued Products, H2 2016
  • Obesity - Discontinued Products (Contd..1), H2 2016
  • Obesity - Discontinued Products (Contd..2), H2 2016
  • Obesity - Discontinued Products (Contd..3), H2 2016
  • Obesity - Discontinued Products (Contd..4), H2 2016
  • Obesity - Discontinued Products (Contd..5), H2 2016
  • Obesity - Discontinued Products (Contd..6), H2 2016

List of Figures

  • Number of Products under Development for Obesity, H2 2016
  • Number of Products under Development for Obesity - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top